Results of the multicenter evaluation of the CEDIA Theophylline assay.
We report on the results of the multicenter evaluation of the CEDIA Theophylline assay on Boehringer Mannheim/Hitachi analyzers in 15 clinical laboratories in Europe and U.S.A. Main items of investigation were imprecision, recovery of control sera, interlaboratory survey and method comparisons using patient samples. Imprecision was found to be comparable to other routine methods. An advantage of the CEDIA assay can be seen in the good interlaboratory transferability of results. The new test has been shown to measure very accurately particularly by comparison with HPLC procedures revealing highly correspondent results. The reagent can be used up to one month using multiple recalibration. Due to its high practicability and reliability the CEDIA Theophylline assay can be recommended as a very suitable routine method for therapeutic drug monitoring on random access analyzers like Boehringer Mannheim/Hitachi analysis systems.
Klein
G
G
Boehringer Mannheim GmbH, Federal Republic of Germany.
Castiñeiras
M J
MJ
Collinsworth
W
W
Courbe
A
A
Delavenne
M
M
Hänseler
E
E
Hannak
D
D
Kaspar
P
P
Kattermann
R
R
Knoke
A
A
D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000295:instrumentation*; D006801:Humans; D007124:Immunoenzyme Techniques / Q000295:instrumentation*; D011786:Quality Control; D013806:Theophylline / Q000008:administration & dosage / Q000493:pharmacokinetics*
D013806:Theophylline